Alkermes Plc (ALKS)vsUnited Therapeutics Corporation (UTHR)
ALKS
Alkermes Plc
$45.97
-0.30%
HEALTHCARE · Cap: $7.63B
UTHR
United Therapeutics Corporation
$497.11
-1.34%
HEALTHCARE · Cap: $21.36B
Smart Verdict
WallStSmart Research — data-driven comparison
United Therapeutics Corporation generates 89% more annual revenue ($3.15B vs $1.67B). UTHR leads profitability with a 41.6% profit margin vs 4.0%. ALKS appears more attractively valued with a PEG of 1.96. UTHR earns a higher WallStSmart Score of 61/100 (C+).
ALKS
Hold46
out of 100
Grade: D+
UTHR
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+54.4%
Fair Value
$76.49
Current Price
$45.97
$30.52 discount
Margin of Safety
+0.8%
Fair Value
$479.95
Current Price
$497.11
$17.16 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 27.0% year-over-year
Keeps 42 of every $100 in revenue as profit
Strong operational efficiency at 42.2%
Safe zone — low bankruptcy risk
Every $100 of equity generates 20 in profit
Attractively priced relative to earnings
Areas to Watch
Expensive relative to growth rate
4.0% margin — thin
Premium valuation, high expectations priced in
Earnings declined 99.4%
Expensive relative to growth rate
Revenue declined 1.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : ALKS
The strongest argument for ALKS centers on Revenue Growth. Revenue growth of 27.0% demonstrates continued momentum.
Bull Case : UTHR
The strongest argument for UTHR centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 41.6% and operating margin at 42.2%.
Bear Case : ALKS
The primary concerns for ALKS are PEG Ratio, Profit Margin, P/E Ratio. A P/E of 119.7x leaves little room for execution misses. Thin 4.0% margins leave little buffer for downturns.
Bear Case : UTHR
The primary concerns for UTHR are PEG Ratio, Revenue Growth.
Key Dynamics to Monitor
ALKS profiles as a growth stock while UTHR is a declining play — different risk/reward profiles.
UTHR carries more volatility with a beta of 0.56 — expect wider price swings.
ALKS is growing revenue faster at 27.0% — sustainability is the question.
UTHR generates stronger free cash flow (206M), providing more financial flexibility.
Bottom Line
UTHR scores higher overall (61/100 vs 46/100), backed by strong 41.6% margins. ALKS offers better value entry with a 54.4% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alkermes Plc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Alkermes plc, a biopharmaceutical company, researches, develops and markets pharmaceutical products to address the unmet medical needs of patients in various therapeutic areas in the United States, Ireland and internationally. The company is headquartered in Dublin, Ireland.
Visit Website →United Therapeutics Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?